IC
GLUE icon

IEQ Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

IEQ Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Sell
18,959
-43,744
-70% -$827K ﹤0.01% 1434
2026
Q1 		$1.03M Sell
62,703
-26,565
-30% -$508K ﹤0.01% 1037
2025
Q4 		$1.4M Buy
89,268
+30,202
+51% +$407K ﹤0.01% 907
2025
Q3 		$438K Sell
59,066
-14,909
-20% -$79K ﹤0.01% 1364
2025
Q2 		$334K Buy
+73,975
New +$330K ﹤0.01% 1339

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IEQ Capital's GLUE Position: Q2 2026 in Review

IEQ Capital reduced its Monte Rosa Therapeutics (GLUE) stake by 70% in Q2 2026, selling an estimated $827K and leaving 18,959 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #1434.

IEQ Capital first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.4M in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • IEQ Capital held 18,959 shares of Monte Rosa Therapeutics worth $459K as of Q2 2026.
  • IEQ Capital sold 43,744 Monte Rosa Therapeutics shares in Q2 2026, an estimated $827K.
  • Monte Rosa Therapeutics made up ﹤0.01% of IEQ Capital's portfolio in Q2 2026, its #1434 holding.
  • IEQ Capital first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • IEQ Capital's Monte Rosa Therapeutics position peaked at $1.4M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.